Synergistic Combinations With the Dual RAF/MEK Inhibitor VS-6766 to Overcome Resistance Mechanisms Clinical Combinations: Dual RAF-MEK & FAK Inhibition for the Treatment of KRAS Mutant Cancers with a Focus on Low-Grade Serous Ovarian Cancer